Britain and America have signed a significant trade agreement that will keep no levies on British pharmaceutical shipments going into the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase funding on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these vital exports will stay at zero for a timeframe of 36 months.
This development is in response to earlier threats to hike duties on patented drug imports, with increases floated reaching double the cost.
"This agreement between the Britain strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue balance to transatlantic pharmaceutical trade," an announcement noted.
Commercial Importance
Drugs are one of the Britain's largest goods shipped to the America, which is by far the largest destination for major companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to September, the UK sold drugs worth £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that span.
"This agreement secures jobs, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Specific NHS Changes
The deal includes several specific changes from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a goal to increase total public funding on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to control costs will be limited at fifteen percent. Previously, repayments exceeded twenty percent.
Broader Context
The pact takes place against a long-running tension between the drug companies and the British authorities over spending levels and NHS adoption.
These tensions were exacerbated by claims that American consumers were paying several times more for the same drugs than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or scrapped, while major investments have been directed toward projects in the United States.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the past decade.
